Unless corrected, the Federal Circuit’s ruling in GSK v. Teva widely threatens the ability of generic and biosimilar developers to deliver more affordable medicines to patients in as timely a manner as possible.
Unless corrected, the Federal Circuit’s ruling in GSK v. Teva widely threatens the ability of generic and biosimilar developers to deliver more affordable medicines to patients in as timely a manner as possible.
Generic and biosimilar medicines make it easier and more affordable for patients to live healthier lives.
Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.
© 2025 Association for Accessible Medicines (AAM), All Rights Reserved
Privacy Policy | Terms of Use | Contact
For the latest updates, follow us on social media.
